Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate zanzalintinib showing potential to offset future revenue losses.

Dr Karen Zaghiyan, who is based out of Los Angeles, says the first item on her list are dairy products with this including ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

A study has found targeting a protein called endocan and its related signaling pathway could be a promising new approach for treating glioblastoma, an aggressive and lethal type of brain cancer.

AI-supported mammography screening significantly increases breast cancer detection rates while maintaining comparable recall ...

A recommended warning against alcohol use by the U.S. surgeon general may boost the fortune of cannabis companies - and could lead to some alcohol companies diversifying by adding cannabis to their ...

Alcohol giants have a hazy future. Late last week, the U.S. surgeon general said beer and spirits cause cancer and should ...

Alcohol companies like Heineken, Constellation Brands, and AB InBev have been preparing for a customer culture shift toward ...

The Dogs of the Dow 2025 pay big dividends—up to 6.8%! Collectively they yield three-times what the broader market pays.

Jefferies investment banker Chris Roop discussed the Big Pharma M&A outlook with Business Insider. Check out the types of ...

U.S. stock futures were little changed Thursday night after a volatile start to the new year. Dow Jones Industrial Average ...

2025 is a year of transformation—and it all starts with some big planetary shifts in January, which will prove once and for ...